News

Medigene to participate in three upcoming international conferences

Press Release

 

Martinsried/Munich, 16 April, 2015. Medigene AG (MDG1, Frankfurt, Prime Standard) announces its participation in three upcoming investment and scientific conferences:
             

  • 8th Kempen & Co Healthcare & Life Sciences Conference

            Date: 16 April 2015
            Location: New York, USA
             

  • AACR Annual Meeting 2015

            Date: 18 - 22 April 2015
            Location: Philadelphia, USA
            Medigene's academic partner, the Oslo University Hospital (Prof. Gunnar Kvalheim, Head of Department of Cellular Therapy) will present clinical data of its DC vaccine program.[1]
            Presentation Time: Monday, 20 April 2015, 1:00 pm - 5:00 pm local time
             

  • 3rd CIMT Endeavour Workshop

            Date: 12 May 2015
            Location: Mainz, Germany
            Prof. Dolores J. Schendel, Chief Scientific Officer, Medigene AG will give a presentation titled "The long and short history of Trianta Immunotherapies: From virtual academic spin-out to subsidiary of Medigene AG"
             

Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. Medigene concentrates on the development of personalized T cell immunotherapies with a focus on haematological malignancies. Medigene is the first German biotech company to have revenues from a marketed product, which is distributed by commercial partner companies. Medigene has advanced drug candidates which are licensed to partners and additional candidates in clinical development. The company is developing highly innovative treatment platforms concentrating on cancer and autoimmune diseases. For more information, please visit www.medigene.com.

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® EndoTAG® and Veregen® are registered trademarks of Medigene AG. These trademarks may be owned or licensed in select locations only.

Contact Medigene
Julia Hofmann, Anja Clausnitzer
Tel.: +49 - 89 - 20 00 33 - 33 01
Email: investor@medigene.com

To unsubscribe from the press release distribution list, please visit: www.medigene.de/unsubscribe


[1] The Oslo University Hospital has an agreement with Medigene for use of Medigene`s new generation DC vaccines for their ongoing academic clinical studies.